Skip to main content
Clinical Trials/NL-OMON53010
NL-OMON53010
Recruiting
Not Applicable

Improving the clinical usefulness of skin biopsy in small fiber neuropathy: examining the intraepidermal nerve fiber density dynamic longitudinally and the importance of adding the proximal/distal ratio - Improving the clinical usefulness of skin biopsy in small fiber neuropathy

Medisch Universitair Ziekenhuis Maastricht0 sites280 target enrollmentTBD

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
small fiber neuropathy
Sponsor
Medisch Universitair Ziekenhuis Maastricht
Enrollment
280
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Observational invasive

Investigators

Sponsor
Medisch Universitair Ziekenhuis Maastricht

Eligibility Criteria

Inclusion Criteria

  • Group 1 (n\=40\) Idiopathic SFN, with normal IENFD:
  • a) Male and female subjects of 18 years or older.
  • b) \>\=2 positive answers on the SFN\-SIQ, not otherwise explained.
  • c) Normal IENFD and abnormal TTT, according to the international normative
  • values,3,23 during the regular visit in our clinical center at least one year
  • d) Written informed consent.Group 2 (n \= 40\) Sodium channelopathy\-related SFN,
  • with normal IENFD:
  • a) Male and female subjects of 18 years or older.
  • b) \>\=2 positive answers on the SFN\-SIQ, not otherwise explained.
  • c) Normal IENFD and abnormal TTT, according to the international normative

Exclusion Criteria

  • All patient groups:
  • a) Underlying cause of SFN (diabetes, hypothyroidism, renal failure, vitamin
  • B12 deficiency, monoclonal gammopathy, alcohol abuse (more than 5 IU/day),
  • malignancies, drugs that cause neuropathy (e.g. chemotherapy, amiodarone,
  • propafenone)).
  • b) Large nerve fiber involvement (i.e. weakness, loss of vibration sense,
  • hypo\-/areflexia, abnormal nerve conduction studies).Groups 1, 4 and 5
  • a) Possibly pathogenic, probably pathogenic or pathogenic NaV1\.7, Nav1\.8 and/or
  • NaV1\.9 variant.Healthy subjects
  • a) \>1 positive answer on the SFN\-SIQ.

Outcomes

Primary Outcomes

Not specified

Similar Trials